Released on: February 4, 2008, 9:52 am

Press Release Author: Samaritan Pharmaceuticals

Industry: Biotech

Press Release Summary: Samaritan will grant CHDI an 18-month non-exclusive license
to evaluate the usefulness of six of Samaritan\'s Alzheimer\'s drugs, SP-233, Sp-sc4,
Sp-sc7, Sp-04, Sp-04m, and Sp-08, as possible therapeutics for HD. CHDI will pay for
the cost of this evaluation and Samaritan will retain all rights in its compounds.


Press Release Body: CHDI Foundation\'s Initial Due Diligence Finds Neuroprotective
Properties of Samaritan\'s Alzheimer\'s Drug\'s Intriguing

Samaritan Pharmaceuticals, Inc. (OTC BB:SPHC.OB - Website), a biopharmaceutical
company focused on bringing innovative life-saving drugs to suffering patients, has
entered into an agreement with CHDI Foundation, Inc. CHDI is a nonprofit
organization pursuing the discovery and development of drugs to delay or slow the
progression of Huntington\'s disease (HD), an inherited disorder that causes
programmed degeneration of brain cells. Per the agreement, Samaritan will grant CHDI
an 18-month non-exclusive license to evaluate the usefulness of six of Samaritan\'s
Alzheimer\'s drugs, SP-233, Sp-sc4, Sp-sc7, Sp-04, Sp-04m, and Sp-08, as possible
therapeutics for HD. CHDI will pay for the cost of this evaluation and Samaritan
will retain all rights in its compounds.

Dr. Janet Greeson, Chief Executive Officer of Samaritan, commented: \"We believe our
CNS drugs hold a lot of promise to cognitively improve Alzheimer\'s patients and
protect their brain from further damage; so we are extremely hopeful our drugs will
demonstrate and hold the same promise for Huntington\'s disease.\"

Robert Pacifici, CHDI\'s Chief Scientific Officer, stated, \"We are intrigued with the
potential that Samaritan\'s neuroprotective drugs have in combating Huntington\'s
disease and look forward to evaluating the Company\'s portfolio of Alzheimer\'s drugs.
CHDI is dedicated to researching therapies that could help Huntington\'s disease
patients and our team looks forward to the collaboration with Samaritan.\'\'

About Huntington\'s Disease
Huntington\'s disease is a familial disease, passed from parent to child through a
mutation in a gene. Each child of an HD parent has a 50-50 chance of inheriting the
HD gene, which causes programmed degeneration of brain cells and results in
emotional disturbance, loss of intellectual faculties and uncontrolled movements.
Most people with HD develop the symptoms at midlife but in some people onset occurs
in infancy or old age. The average survival time after onset is approximately
fifteen to twenty years. It is estimated that about one in every 10,000 persons has
the HD gene. At this time, there is no way to stop or reverse the course of HD.

About CHDI Foundation, Inc.
CHDI Foundation, Inc. is a non-profit organization pursuing a biotech approach to
rapidly discover and develop drugs that prevent or slow Huntington\'s disease.
Through collaborations with academic and industrial partners, CHDI participates in
all aspects of drug discovery and development from discovery research through
clinical development.

About Samaritan Pharmaceuticals

Samaritan Pharmaceuticals: \"Transforming Today\'s Science Into Tomorrow\'s Cures...\'\'
Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company committed
to bringing innovative life-saving drugs to suffering patients.

Website: http://www.samaritanpharma.com Please register so we can notify you of
upcoming conference calls, news and events.

Disclaimer
The company disclaims any information created by an outside party and endorses only
information communicated by its press releases, filings, and website. This news
release contains forward-looking statements that reflect management\'s current
beliefs about the potential for its drug candidates, science, and technology.
However, as with any biopharmaceutical under development, there are significant
risks and uncertainties in the process of development and regulatory review. There
are no guarantees that products will prove to be commercially successful. For
additional information about the factors that affect the company\'s business, please
read the company\'s latest Form 10-Q filed November 19, 2007. The company undertakes
no duty to update forward-looking statements.

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
(212) 825-3210


Web Site:
http://www.samaritanpharma.com/news_01-24-08_Huntington_Disease_Foundation_to_Assess_Six_of_Samaritans_Drugs_for_Potential_to_Delay_or_Slow_Progression_of_the_Disease.asp


Contact Details: Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
(212) 825-3210

Samaritan Pharmaceuticals
101 Convention Center Drive
Suite 310
Las Vegas, NV 89109
702-735-7001